Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Polyphor
Polyphor
Activities:
Research & Development
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development
Kalina Scott appointed new CFO of Polyphor
Research & Development
New hope against antibiotic resistance: Outer-Membrane Protein Targeting Antibiotics
OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens
Recruitment
Debra Barker appointed as new CMDO of Polyphor
Polyphor has announced the appointment of Dr Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO)
Research & Development
Polyphor appoints Michael Altorfer as Chief Executive
He replaces Jean-Pierre Obrecht, who will continue as a member of the Board of Directors
Research & Development
Roche signs licensing agreement with Polyphor to combat multi-drug resistant infections
Makes an upfront payment of CHF35m to Polyphor in deal that could be worth up to CHF500m
Research & Development
Polyphor signs MacroFinder collaboration with Boehringer Ingelheim
Will use technology to identify drug candidates addressing therapeutic targets chosen by BI
Subscribe now